Guggenheim Capital’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$38.4M Buy
1,367,689
+159,332
+13% +$4.24M 0.3% 67
2025
Q4
$30.1M Buy
1,208,357
+41,805
+4% +$1.05M 0.22% 96
2025
Q3
$29.7M Buy
1,166,552
+19,388
+2% +$479K 0.22% 92
2025
Q2
$27.8M Sell
1,147,164
-25,763
-2% -$601K 0.22% 94
2025
Q1
$29.7M Sell
1,172,927
-74,096
-6% -$1.94M 0.27% 81
2024
Q4
$33.1M Sell
1,247,023
-75,970
-6% -$2.06M 0.27% 78
2024
Q3
$38.3M Sell
1,322,993
-107,587
-8% -$3.14M 0.27% 70
2024
Q2
$40M Sell
1,430,580
-41,646
-3% -$1.15M 0.28% 68
2024
Q1
$40.9M Buy
1,472,226
+52,909
+4% +$1.47M 0.29% 65
2023
Q4
$40.9M Buy
1,419,317
+54,297
+4% +$1.64M 0.31% 53
2023
Q3
$45.3M Buy
1,365,020
+158,352
+13% +$5.6M 0.39% 41
2023
Q2
$44.3M Buy
1,206,668
+70,367
+6% +$2.74M 0.35% 48
2023
Q1
$46.4M Sell
1,136,301
-85
-0% -$3.67K 0.39% 43
2022
Q4
$58.2M Sell
1,136,386
-46,526
-4% -$2.23M 0.51% 22
2022
Q3
$51.8M Sell
1,182,912
-45,763
-4% -$2.22M 0.47% 24
2022
Q2
$64.4M Sell
1,228,675
-157,294
-11% -$8.02M 0.51% 21
2022
Q1
$71.8M Sell
1,385,969
-159,853
-10% -$8.29M 0.43% 32
2021
Q4
$91.3M Buy
1,545,822
+29,250
+2% +$1.45M 0.48% 27
2021
Q3
$65.2M Buy
1,516,572
+72,600
+5% +$3.22M 0.39% 31
2021
Q2
$56.5M Sell
1,443,972
-17,536
-1% -$682K 0.33% 44
2021
Q1
$53M Buy
1,461,508
+40,497
+3% +$1.44M 0.35% 41
2020
Q4
$52.3M Buy
1,421,011
+1,929
+0.1% +$70.8K 0.33% 40
2020
Q3
$49.4M Sell
1,419,082
-51,732
-4% -$1.81M 0.36% 39
2020
Q2
$45.6M Buy
1,470,814
+82,702
+6% +$2.81M 0.35% 41
2020
Q1
$43M Sell
1,388,112
-86,702
-6% -$2.95M 0.43% 28
2019
Q4
$54.8M Sell
1,474,814
-80,168
-5% -$2.86M 0.41% 32
2019
Q3
$53M Buy
1,554,982
+11,594
+0.8% +$422K 0.42% 27
2019
Q2
$63.4M Sell
1,543,388
-7,676
-0.5% -$305K 0.52% 17
2019
Q1
$62.5M Buy
1,551,064
+71,947
+5% +$2.88M 0.51% 16
2018
Q4
$61.3M Sell
1,479,117
-265,066
-15% -$11M 0.52% 16
2018
Q3
$72.9M Buy
1,744,183
+93,536
+6% +$3.6M 0.48% 15
2018
Q2
$56.8M Sell
1,650,647
-1,710,999
-51% -$58.5M 0.38% 24
2018
Q1
$113M Sell
3,361,646
-78,960
-2% -$2.71M 0.28% 33
2017
Q4
$118M Buy
3,440,606
+159,903
+5% +$5.45M 0.28% 30
2017
Q3
$111M Sell
3,280,703
-129,945
-4% -$4.18M 0.26% 28
2017
Q2
$109M Buy
3,410,648
+420,584
+14% +$13.3M 0.29% 25
2017
Q1
$97M Sell
2,990,064
-167,287
-5% -$5.27M 0.26% 35
2016
Q4
$97.3M Buy
3,157,351
+457,206
+17% +$14M 0.28% 31
2016
Q3
$86.8M Sell
2,700,145
-200,568
-7% -$6.71M 0.27% 34
2016
Q2
$96.9M Sell
2,900,713
-195,265
-6% -$6.23M 0.3% 27
2016
Q1
$87.1M Sell
3,095,978
-206,071
-6% -$5.89M 0.27% 32
2015
Q4
$101M Buy
3,302,049
+20,087
+0.6% +$632K 0.29% 25
2015
Q3
$97.8M Sell
3,281,962
-561,875
-15% -$18M 0.3% 19
2015
Q2
$122M Buy
3,843,837
+198,126
+5% +$6.46M 0.3% 18
2015
Q1
$120M Sell
3,645,711
-230,732
-6% -$7.34M 0.28% 20
2014
Q4
$115M Buy
3,876,443
+369,577
+11% +$10.6M 0.29% 24
2014
Q3
$98.4M Buy
3,506,866
+16,839
+0.5% +$473K 0.24% 33
2014
Q2
$98.3M Buy
3,490,027
+424,767
+14% +$12.1M 0.25% 32
2014
Q1
$93.4M Buy
3,065,260
+367,860
+14% +$11M 0.27% 29
2013
Q4
$78.4M Buy
2,697,400
+204,104
+8% +$5.94M 0.24% 43
2013
Q3
$67.9M Sell
2,493,296
-75,871
-3% -$2.06M 0.24% 40
2013
Q2
$68.3M Buy
+2,569,167
New +$71M 0.29% 28

Other funds holding PFE

Guggenheim Capital's PFE Position: Q1 2026 in Review

Guggenheim Capital increased its Pfizer (PFE) stake by 13% in Q1 2026, buying an estimated $4.24M and bringing the position to 1,367,689 shares worth $38.4M. The position accounts for 0.3% of the portfolio, ranked #67.

Guggenheim Capital first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $122M in Q2 2015. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Guggenheim Capital held 1,367,689 shares of Pfizer worth $38.4M as of Q1 2026.
  • Guggenheim Capital bought 159,332 Pfizer shares in Q1 2026, an estimated $4.24M.
  • Pfizer made up 0.3% of Guggenheim Capital's portfolio in Q1 2026, its #67 holding.
  • Guggenheim Capital first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Guggenheim Capital's Pfizer position peaked at $122M in Q2 2015.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.